Videos

Shannon N. Westin, MD, MPH, discusses resistance seen with PARP inhibitors in ovarian cancer and how this resistance can be overcome.

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.

Lori J. Wirth, MD, discusses the role of lenvatinib in the treatment landscape of differentiated thyroid cancer and how this might evolve in the future.

Frontline Treatment Options for Hodgkin's Lymphoma

Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.

Simon Rule, MD, PhD, shares his treatment considerations for select patients with mantle cell lymphoma.

Ann-Lii Cheng, MD, discusses where the of hepatocellular carcinoma is headed.

Ulrik Lassen, MD, PhD, discusses the updated response findings with larotrectinib in TRK+ cancers.

Juergen Wolf, MD, medical director, Center for Integrated Oncology (CIO) at the University Hospital Cologne, discusses the phase II findings of the GEOMETRY mono-1 study in patients with MET exon 14-mutated advanced non-small cell lung cancer.

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma. 

Sarah K. Tasian, MD, discusses what she finds most interesting about Philadelphia chromosome (Ph-like) acute lymphoblastic leukemia.

Julie M. Vose, MD, MBA, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.

Cathy Eng, MD, discusses how the PRODIGE 7 trial, though negative, provided valuable evidence to the field for treatment of patients with metastatic colorectal cancer with peritoneal carcinomatosis.

Paolo A. Ascierto, MD, discusses how results from the COLUMBUS trial affect the treatment landscape for patients with BRAF-mutant melanoma.

Daniel A. Pollyea, MD, MS, discusses how far the field of acute myeloid leukemia has come in the last 1 to 2 years.

Danielle Brander, MD, discusses the current treatment landscape in the frontline setting for patients with chronic lymphocytic leukemia.

Krishnansu S. Tewari, MD, discusses the excitement around immunotherapy in cervical cancer. 

Eric Smith, MD, PhD, discusses challenges with CAR T-cell therapy as a treatment option for multiple myeloma. While studies have shown CD19 CAR T cells and BCMA CAR T cells have durable responses in this patient population, patients still relapse over time.

Hassane M. Zarour, MD, discusses the addition of antibiotics to immunotherapy treatment in patients with melanoma. 

Riccardo Lencioni, MD, discusses how to successfully integrate Liver Imaging Reporting and Data Systems their clinical practice.<br /> &nbsp;

Masatoshi Kudo, MD, PhD, discusses the potential for systemic therapy in the adjuvant setting of hepatocellular carcinoma. While current trials are investigating this therapy in advanced stage HCC, Kudo believes it could benefit patients following a surgery resecting an aberration.

Fabrice Barlesi, MD, discusses the importance of molecular testing in patients with nonsquamous non&ndash;small cell lung cancer during the&nbsp;World Conference on Lung Cancer in Toronto, Canada.

Jonathon B. Cohen, MD, discusses findings from a study of polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, with bendamustine and rituximab in patients with aggressive lymphomas.

David Spigel, MD, medical oncologist and Chief Scientific Officer at Sarah Cannon Research Institute, discusses the updated results for the PACIFIC trial, a randomized phase III trial investigating the addition of durvalumab (Imfinzi) to chemoradiation versus placebo in patients with unresectable stage III lung cancer.